Tracks enavogliflozin tablets in type 2 diabetes with high blood pressure or cholesterol
Follows adults with type 2 diabetes and high blood pressure or cholesterol taking enavogliflozin tablets.
Key facts
- Who runs it
- Daewoong Pharmaceutical Co. LTD.
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Evaluation of Enavogliflozin's Efficacy and Safety in Type II Diabetes With Hypertension or Dyslipidemia
- Status
- Recruiting
- People taking part
- 12,000 people, planned
- Started
- 3 Dec 2024
- Planned end
- 30 Jun 2026
- Type of study
- Observational
- Treatments tested
- Envlo Tablet
- Envlomet SR Tablet
- Record updated
- 23 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for adults with type 2 diabetes who also have high blood pressure or high blood fat levels. They are taking, or about to take, Envlo or Envlomet SR tablets.
- Age
- 19 years and older
- Sex
- Men and women can join.
- Disease stage
- Type 2 diabetes together with hypertension (high blood pressure) or dyslipidemia (abnormal blood fats).
- Earlier treatment
- Must be taking, or be scheduled to take, Envlo Tab or Envlomet SR Tab. No weight-loss treatment or unstable weight in the last 3 months before enrollment.
Main reasons for not taking part
- Type 1 diabetes, diabetic ketoacidosis, gestational diabetes or other non-type 2 diabetes
- Kidney function (eGFR) below 60 ml/min/1.73m², end-stage kidney disease or dialysis
- Moderate or severe liver failure
- Heart failure class III or IV (NYHA)
- Pregnant or breastfeeding women
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- An adult male and female over 19 years of age
- A patient diagnosed with type 2 diabetes who have hypertension or dyslipidemia and are currently receiving Envlo Tab/ Envlomet SR Tab or are scheduled to receive Envlo Tab/ Envlomet SR Tab
- A person who voluntarily participates in the observational study and agrees in writing to comply with the subject's precautions during the study period after hearing and understanding the detailed explanation of the characteristics of the observational study and the drug to be studied 4 ) A person who understands the content of this observational study, are cooperative with the research process, and are considered capable of participating until the study's completion
Who cannot take part
- Patients with unstable weight due to treatment or other treatments (surgery, diet, etc.) with obesity or weight loss medication within 3 months of Enrollment
- A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices
- A patient with diabetes other than type 2 diabetes (type 1 diabetes, diabetic ketoacidosis, gestational diabetes, etc.)
- Among patients who begin treatment with Envlo Tab/ Envlomet Tab at the time of registration, those with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m²
- A person who is prohibited from administering in accordance with the permission of Envlo Tab's; Patients who overreact to Envlo Tab or Envlomet Tab components and have a history of it; Patients with an estimated glomerular filtration rate (eGFR) of less than 60 ml/min/1.73m², end-stage renal disease, or on dialysis; Patients with moderate and severe liver failure (AST or ALT > 3x normal upper limit, Total Bilirubin > 2x normal upper limit, hepatitis or liver failure); Class III or IV by classification of the New York Heart Association (NYHA)
- Pregnant women and lactating women
- A person who is considered inappropriate to participate in this observational study based on the judgment of investigators
Where in South Korea
- Happy Yonsei Family Medicine ClinicSeoul, South KoreaContact: Sang Hoon MoonTaking people
About the trial
What the trial wants to find out
This observational study is a non-interventional, multi-center, prospective observational study aimed at tracking the efficacy and safety of Envlo or Envlomet SR tablets for 24 weeks in patients with type 2 diabetes and hypertension or dyslipidemia who are currently taking or are scheduled to take Envlo or Envlomet SR tablets in an actual clinical setting.
Treatments tested
- Envlo Tablet
- Envlomet SR Tablet
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-Center, Observational Study to Evaluate the Efficacy and Safety of Enavogliflozin in Patients With Type II Diabetes Mellitus Accompanied by Hypertension or Dyslipidemia
- Plain-language title
- Tracks enavogliflozin tablets in type 2 diabetes with high blood pressure or cholesterolGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 23 January 2025